Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
J Clin Microbiol. 2018 Aug 27;56(9). doi: 10.1128/JCM.00365-18. Print 2018 Sep.
Molecular methods are often used for detection, but complete definition of antimicrobial resistance (AMR) patterns still requires phenotypic tests. We developed an assay that both identifies and detects AMR determinants in clinical specimens. We designed a mismatch amplification mutation assay (MAMA)-based SYBR green real-time PCR targeting one -specific region (); mosaic alleles (Asp345 deletion [Asp345del], Gly545Ser) associated with decreased susceptibility to cephalosporins; and alterations conferring resistance to ciprofloxacin (GyrA Ser91Phe), azithromycin (23S rRNA A2059G and C2611T), and spectinomycin (16S rRNA C1192T). We applied the real-time PCR to 489 clinical specimens, of which 94 had paired culture isolates, and evaluated its performance by comparison with the performance of commercial diagnostic molecular and phenotypic tests. Our assay exhibited a sensitivity/specificity of 93%/100%, 96%/85%, 90%/91%, 100%/100%, and 100%/90% for the detection of directly from urethral, rectal, pharyngeal, cervical, and vaginal samples, respectively. The MAMA strategy allowed the detection of AMR mutations by comparing cycle threshold values with the results of the reference reaction. The method accurately predicted the phenotype of resistance to four antibiotic classes, as determined by comparison with the MIC values obtained from 94 paired cultures (sensitivity/specificity for cephalosporins, azithromycin, ciprofloxacin, and spectinomycin resistance, 100%/95%, 100%/100%, 100%/100%, and not applicable [NA]/100%, respectively, in genital specimens and NA/72%, NA/98%, 100%/97%, and NA/96%, respectively, in extragenital specimens). False-positive results, particularly for the Asp345del reaction, were observed predominantly in pharyngeal specimens. Our real-time PCR assay is a promising rapid method to identify and predict AMR directly in genital specimens, but further optimization for extragenital specimens is needed.
分子方法常用于检测,但完全定义抗生素耐药(AMR)模式仍需要表型试验。我们开发了一种既能鉴定又能检测临床标本中 AMR 决定因素的检测方法。我们设计了一种基于错配扩增突变检测(MAMA)的 SYBR 绿色实时 PCR,针对一个特定区域();与头孢菌素敏感性降低相关的马赛克等位基因(Asp345 缺失[Asp345del]、Gly545Ser);以及赋予对环丙沙星(GyrA Ser91Phe)、阿奇霉素(23S rRNA A2059G 和 C2611T)和壮观霉素(16S rRNA C1192T)耐药性的改变。我们将实时 PCR 应用于 489 份临床标本,其中 94 份有配对培养分离物,并通过与商业诊断分子和表型检测的性能比较来评估其性能。我们的检测方法在直接从尿道、直肠、咽部、宫颈和阴道样本中检测的灵敏度/特异性分别为 93%/100%、96%/85%、90%/91%、100%/100%和 100%/90%。MAMA 策略通过比较循环阈值值与参考反应的结果来检测 AMR 突变。该方法通过与 94 对培养物获得的 MIC 值进行比较,准确预测了对四种抗生素类别的表型耐药性(生殖道标本中头孢菌素、阿奇霉素、环丙沙星和壮观霉素耐药的灵敏度/特异性,100%/95%、100%/100%、100%/100%和不适用[NA]/100%,分别为 100%/100%、不适用[NA]/100%、100%/100%和不适用[NA]/100%,外生殖道标本中分别为 100%/97%和不适用[NA]/96%)。假阳性结果,特别是在咽标本中,主要观察到 Asp345del 反应。我们的实时 PCR 检测方法是一种有前途的快速方法,可直接在生殖道标本中鉴定和预测 AMR,但需要进一步优化外生殖道标本。